<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pulmonary lymphomatoid granulomatosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pulmonary lymphomatoid granulomatosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pulmonary lymphomatoid granulomatosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Nicholson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary lymphomatoid granulomatosis (PLG) is an uncommon Epstein-Barr virus-associated lymphoproliferative disorder characterized by multiple pulmonary nodular lesions with lymphocytic invasion of vascular walls on biopsy [
         <a href="#rid1">
          1-6
         </a>
         ]. The clinical implications of this lesion have been controversial, as evidenced by a long list of competing synonyms including angiocentric immunoproliferative lesion and angiocentric lymphoma [
         <a href="#rid7">
          7-9
         </a>
         ].
        </p>
        <p>
         Pulmonary lymphomatoid granulomatosis will be reviewed here. Clinical aspects of other pulmonary lymphocytic and lymphoproliferative disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4361.html" rel="external">
          "Lymphoid interstitial pneumonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4694.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4707.html" rel="external">
          "HHV-8/KSHV-associated multicentric Castleman disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         PLG generally presents between the ages of 30 and 50, although patients can be affected at any age [
         <a href="#rid9">
          9-16
         </a>
         ]. It is predominantly seen in men, with an estimated male to female ratio of at least 2:1 [
         <a href="#rid2">
          2,17
         </a>
         ]. The effects of race and geography on disease incidence are not known, although a higher diagnosis rate is reported in Western countries [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         PLG is associated with Epstein-Barr virus (EBV) infection in most if not all cases [
         <a href="#rid2">
          2,3
         </a>
         ], in that “negative” cases may reflect grade 1 disease with infrequent EBV-positive cells that were not detected [
         <a href="#rid18">
          18-20
         </a>
         ]. (See
         <a class="local">
          'EBV in situ hybridization and grading'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Lymphomatoid granulomatosis'
         </a>
         .)
        </p>
        <p>
         Patients with an underlying immunodeficiency (eg, Wiskott-Aldrich, X-linked severe combined immunodeficiency [SCID], immunosuppression post allogeneic organ transplantation, dedicator of cytokinesis 8 [DOCK8] deficiency, HIV infection) or a lymphoproliferative disorder are at increased risk of developing PLG [
         <a href="#rid2">
          2,10,11,21-25
         </a>
         ]. These immune defects may lead to an abnormal host response to EBV infection, resulting in lymphomatoid granulomatosis rather than clearance of the viral infection [
         <a href="#rid2">
          2,7
         </a>
         ].
        </p>
        <p>
         PLG may develop as a consequence of the immunosuppression induced by certain medications. Rare cases of PLG have been reported in patients being treated with
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , and
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         with resolution sometimes following cessation of the medication [
         <a href="#rid26">
          26-34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The lung is the most commonly involved organ (&gt;90 percent) [
         <a href="#rid2">
          2
         </a>
         ]. The skin (20 to 50 percent), kidney (15 to 32 percent), neurologic system (20 to 38 percent), and liver (12 to 19 percent) may be affected concurrently or independently [
         <a href="#rid2">
          2,10,23
         </a>
         ]. Less commonly, patients have involvement of other organ systems, such as the eyes, hard palate, gastrointestinal tract, and genitourinary tract [
         <a href="#rid2">
          2,7,10,35-38
         </a>
         ]. Involvement of the spleen and lymph nodes is rare [
         <a href="#rid2">
          2,23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Lymphomatoid granulomatosis'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms
         </strong>
         – The most common presenting symptoms are cough (60 percent of patients), fever (60 percent), rash/nodules (40 percent), malaise (35 percent), weight loss (35 percent), neurologic abnormalities (30 percent), dyspnea (30 percent), and chest pain (15 percent) [
         <a href="#rid10">
          10
         </a>
         ]. Rarely, patients are asymptomatic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         – Physical examination of the lungs is generally normal, although basilar crackles have been reported [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Extrapulmonary involvement may be more readily apparent, as examination of the skin can reveal single or multiple, pink-to-purple, dermal or subcutaneous nodules with or without ulceration [
         <a href="#rid40">
          40
         </a>
         ]. Plaque-like skin changes are also described. The skin lesions are generally painless, but can occasionally be tender and pruritic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neurologic involvement is often manifested by ataxia, cranial nerve abnormalities (eg, hearing loss, diplopia, dysarthria), peripheral neuropathy, and altered mental status [
         <a href="#rid2">
          2,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4056330907">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         PLG should be suspected in patients presenting with cough, dyspnea, constitutional symptoms and nodular pulmonary opacities on chest imaging, or, rarely, with asymptomatic pulmonary opacities [
         <a href="#rid2">
          2
         </a>
         ]. Careful skin examination is helpful to identify potential lesions for biopsy. Lymph nodes and spleen are generally not involved.
        </p>
        <p>
         The general evaluation of a patient with multiple pulmonary nodules is described separately. (See
         <a class="medical medical_review" href="/z/d/html/6986.html" rel="external">
          "Diagnostic evaluation of the incidental pulmonary nodule"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Laboratory studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory studies are generally nondiagnostic. Laboratory tests including a complete blood count with white blood cell differential, renal and liver function tests, lactate dehydrogenase (LDH), and urinalysis, should be obtained. Depending on the patient, testing for HIV infection and serum immunoglobulin levels may be appropriate.
        </p>
        <p>
         In PLG, the complete blood cell count is generally normal with occasional mild leukocytosis or leukopenia [
         <a href="#rid1">
          1
         </a>
         ]. Nonspecific abnormalities in immunoglobulins (usually increases in immunoglobulin G [IgG] and immunoglobulin M [IgM]) are seen in the majority of patients [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
         Serologic evidence of previous Epstein-Barr virus (EBV) infection is generally present, although the heterophile test may be negative [
         <a href="#rid10">
          10,14
         </a>
         ]. The serologic evaluation of EBV infection is discussed separately. While not necessary to obtain, the EBV viral load is usually minimally elevated [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">
          "Infectious mononucleosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         In patients with neurologic involvement, lumbar puncture commonly reveals pleocytosis with an elevated protein level [
         <a href="#rid7">
          7,42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">
          "Clinical manifestations and treatment of Epstein-Barr virus infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Lung function testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary function tests (PFTs) may be helpful to determine the severity of respiratory impairment, but no characteristic PFT abnormalities have been reported [
         <a href="#rid9">
          9
         </a>
         ]. Hypoxemia and chronic respiratory alkalosis are reported in association with advanced disease [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1647.html" rel="external">
          "Measures of oxygenation and mechanisms of hypoxemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Imaging studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest radiography typically reveals multiple poorly defined nodules and/or masses in the mid- and lower-lung zones; diffuse reticular abnormalities may also be present [
         <a href="#rid7">
          7,9,17,39
         </a>
         ].
        </p>
        <p>
         Chest computed tomography (CT) usually shows both well and poorly-defined bilateral lung nodules that are predominantly in the lower lung zones and may wax and wane over time [
         <a href="#rid23">
          23,39
         </a>
         ]. Most lesions are less than 1 cm in diameter, but larger cavitary masses have been reported [
         <a href="#rid2">
          2,17,43
         </a>
         ]. Nodules are preferentially located along the bronchovascular structures or interlobular septa  (
         <a class="graphic graphic_diagnosticimage graphicRef52068 graphicRef60848" href="/z/d/graphic/52068.html" rel="external">
          image 1A-B
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Thin walled cystic lesions may also be present  (
         <a class="graphic graphic_diagnosticimage graphicRef71625" href="/z/d/graphic/71625.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6986.html" rel="external">
          "Diagnostic evaluation of the incidental pulmonary nodule"
         </a>
         .)
        </p>
        <p>
         A few case reports have reported variable uptake of 18F-fluorodeoxyglucose (18F-FDG) on positron emission tomographic (PET) scanning [
         <a href="#rid44">
          44-46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4008075534">
         <span class="h2">
          Tissue biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histopathologic examination of involved tissue is necessary to make a diagnosis. When the lung is the primary site of involvement, lung tissue is usually obtained by video-assisted thoracoscopic surgery or thoracotomy, as transthoracic needle aspirate and transbronchial biopsy samples are often too small for adequate evaluation.
        </p>
        <p>
         In a large series, the diagnostic biopsy usually came from the lung (73 percent) or skin (17 percent); additional sites included the liver, kidney, nasal cavity, adrenal gland, gastrointestinal tract, and eyelid/conjunctiva [
         <a href="#rid23">
          23
         </a>
         ]. It is important to perform multiple lung biopsies if the patient has multiple lesions and to include sampling of dominant lesions in order to properly ascertain the grade [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         When present, skin lesions should undergo biopsy for histopathologic and microbiologic studies.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Pathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         An accurate morphologic, immunophenotypic, and genetic analysis of involved tissue is essential for the diagnosis of PLG [
         <a href="#rid6">
          6,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Morphology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histopathologic diagnosis of PLG typically manifests as a triad of polymorphic lymphoid infiltrates, transmural infiltration of arteries and veins by lymphoid cells ("angiitis"), and focal areas of necrosis within the lymphoid infiltrates  (
         <a class="graphic graphic_picture graphicRef74089 graphicRef61309" href="/z/d/graphic/74089.html" rel="external">
          picture 1A-B
         </a>
         ) [
         <a href="#rid1">
          1,2,23
         </a>
         ]. These areas of necrosis gave rise to the term "granulomatosis;" however, well-formed granulomas are typically absent in PLG [
         <a href="#rid2">
          2
         </a>
         ]. Skin lesions may have a more prominent granulomatous reaction in subcutaneous tissue.
        </p>
        <p>
         In the lung, lesions are generally well-circumscribed and composed of small lymphocytes, plasma cells, and a variable number of large atypical mononuclear cells. The majority of the small lymphocytes are T cells, while large atypical cells are usually B cells [
         <a href="#rid47">
          47,48
         </a>
         ]. T cells are polyclonal and represent a "reactive," non-neoplastic population [
         <a href="#rid49">
          49
         </a>
         ]. Variably atypical B cells represent the neoplastic component and show evidence of EBV infection with
         <em>
          in situ
         </em>
         hybridization [
         <a href="#rid2">
          2,5
         </a>
         ]. Reed-Sternberg cells are not present. (See
         <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">
          "Clinical manifestations and treatment of Epstein-Barr virus infection"
         </a>
         .)
        </p>
        <p>
         EBV-positive large B-cell lymphoma is differentiated on the basis of a uniform population of large atypical EBV-positive B cells without a polymorphous background. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Immunophenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         The EBV positive B cells typically express CD20 and may express CD30 [
         <a href="#rid2">
          2
         </a>
         ]. They are negative for CD15. Larger, atypical, pleomorphic cells may be latent membrane protein 1 (LMP1) positive. Epstein Barr virus nuclear antigen-2 (EBNA2) is frequently positive, consistent with latency type III [
         <a href="#rid23">
          23
         </a>
         ]. The background lymphocytes are CD3 positive T cells with a preponderance expressing CD4 rather than CD8, although the proportions can vary [
         <a href="#rid2">
          2,18,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          EBV in situ hybridization and grading
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three histopathologic grades have been proposed, based upon the proportion of EBV-positive large B lymphocytes, as determined by
         <em>
          in situ
         </em>
         hybridization for EBV-encoded small RNA (EBER) [
         <a href="#rid2">
          2,7,50
         </a>
         ]. It is important to differentiate between low grade (grades 1 and 2) and high grade (grade 3) disease, as high grade disease has a less favorable prognosis and is treated like diffuse large B cell lymphoma (DLBCL) with immunochemotherapy [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade
         </strong>
         <strong>
          1
         </strong>
         lesions are either devoid of or contain only scattered EBV-positive cells. It is unclear whether lesions devoid of EBV-positive B cells represent a distinct primary T cell disorder, or an exuberant response to rare (but not visualized) EBV-positive cells [
         <a href="#rid2">
          2,4,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade 2
         </strong>
         lesions contain occasional large lymphoid cells or immunoblasts in a polymorphous background. Clusters of cells positive for CD20 are present, as well as areas of necrosis.
         <em>
          In situ
         </em>
         hybridization demonstrates approximately 5 to 20 EBV-positive cells per high power field, but in some areas up to 50 EBV-positive cells may be seen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade 3
         </strong>
         lesions have an inflammatory background, but large atypical B cells are easily identified by CD20 staining. Necrosis is typically extensive.
         <em>
          In situ
         </em>
         hybridization typically demonstrates numerous EBV positive cells (&gt;50 per high power field), although EBV identification by EBER can be less reliable in large areas of necrosis as RNA is poorly preserved. Other methods of identification of EBV may be helpful (eg, EBV nuclear antigen [EBNA2] polymerase chain reaction) [
         <a href="#rid23">
          23
         </a>
         ]. Grade 3 lesions must be differentiated from more conventional forms of DLBCL. Features such as a uniform population of large atypical EBV-positive cells and absence of a polymorphous background are not typical of PLG and favor a diagnosis of EBV-positive DLBCL not otherwise specified [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Genetic features
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no single cytogenetic change that is characteristic of PLG. Generally, in grades 2 and 3 disease, B cell monoclonality can be demonstrated with testing of the immunoglobulin genes or Southern blot, whereas B cell clonality is inconsistent in grade 1 disease (possibly due to the relative rarity of EBV-positive cells) [
         <a href="#rid2">
          2
         </a>
         ]. Analysis of the T cell receptor gene shows polyclonality. Oncogene alterations have not been reported [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since the clinical presentation of PLG is nonspecific, the diagnosis hinges on lung histopathology showing the classic triad (ie, polymorphic lymphoid infiltrates, transmural infiltration of arteries and veins by lymphoid cells, and focal areas of necrosis) and demonstration of Epstein-Barr virus (EBV) positive B cells by
         <em>
          in situ
         </em>
         hybridization.(See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
         Immunohistochemical analysis that uses antibodies directed against B and T cell-associated antigens is used to determine the proportion and clonality of these cells.
         <em>
          In situ
         </em>
         hybridization is used to establish the presence and proportion of EBV-positive B cells. The presence of large B cells demonstrating EBV-positive cells by
         <em>
          in situ
         </em>
         hybridization with the EBV-encoded small RNA (EBER) probe is definitional for PLG [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         PLG should be distinguished from other lung diseases that present with nodular opacities and lymphocytic infiltration.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sarcoidosis
         </strong>
         – Sarcoidosis is distinguished from PLG by the presence of well-formed granulomas on biopsy. Mediastinal and hilar adenopathy are more common in sarcoidosis than PLG [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fungal infection
         </strong>
         – Coccidioidomycosis and histoplasmosis can present with nodular lung lesions and central nervous system involvement, as can some other fungal infections. Travel history is helpful in identifying patients at risk for coccidioidal and histoplasma infections. Further evaluation with stains, culture, and laboratory tests is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">
          "Primary pulmonary coccidioidal infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2450.html" rel="external">
          "Pathogenesis and clinical features of pulmonary histoplasmosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2451.html" rel="external">
          "Diagnosis and treatment of pulmonary histoplasmosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphoid interstitial pneumonia
         </strong>
         – Lymphoid interstitial pneumonia (LIP) is a benign polyclonal proliferation, usually of mature B or T lymphocytes, that can either involve the lung diffusely or be a focal process, often associated with a rheumatic disease. Since LIP is a benign disorder, the lymphocytic infiltrate, usually B cells, must be polyclonal. (See
         <a class="medical medical_review" href="/z/d/html/4361.html" rel="external">
          "Lymphoid interstitial pneumonia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunoglobulin G4 related disease (IgG4-RD)
         </strong>
         – IgG4-RD can affect multiple organs including the lung. The presenting symptoms overlap with PLG (dyspnea, cough, chest pain). IgG4-RLD often resembles lung cancer in chest images, with imaging findings of nodular solid or ground-glass opacities [
         <a href="#rid52">
          52
         </a>
         ]. While associated lymphadenopathy is common in IgG4-RD, it is uncommon in PLG. Histopathologic features of IgG4-RD include a dense lymphoplasmacytic infiltrate enriched for IgG4-positive plasma cells. (See
         <a class="medical medical_review" href="/z/d/html/121220.html" rel="external">
          "Clinical manifestations and diagnosis of IgG4-related disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Granulomatosis with polyangiitis (GPA)
         </strong>
         – While prominent vascular infiltration with inflammatory cells and arterial narrowing are noted in PLG, vessel wall necrosis, a feature of GPA, is generally minimal to absent. In addition, multinucleated giant cells are not seen in lymphomatoid granulomatosis, but are often seen in PGA [
         <a href="#rid2">
          2
         </a>
         ]. A positive test for antineutrophil cytoplasmic antibody further supports a diagnosis of GPA. (See
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multicentric Castleman disease (MCD)
         </strong>
         – MCD is a lymphoproliferative disorder that typically presents with lymphadenopathy in multiple lymph node regions. A spectrum of lung parenchymal findings may be present, including subpleural nodules, interlobular septal thickening, peribronchovascular thickening, ground glass opacities, and patchy, rounded areas of consolidation. In approximately half the patients, MCD is associated with human herpes virus-8 (HHV-8) infection. (See
         <a class="medical medical_review" href="/z/d/html/4707.html" rel="external">
          "HHV-8/KSHV-associated multicentric Castleman disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117312.html" rel="external">
          "HHV-8-negative/idiopathic multicentric Castleman disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epstein Barr virus (EBV)-positive diffuse large B cell lymphoma (DLBCL)
         </strong>
         – EBV-positive DLBCL, not otherwise specified (NOS), is a clonal B cell lymphoproliferative disorder seen in patients without known immunodeficiency and typically presents with extranodal disease. The diagnosis of EBV-positive DLBCL is made when a uniform population of large, atypical EBV-positive B cells is noted without the polymorphous background population of cells that characterizes PLG [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'EBV-positive DLBCL, NOS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extranodal natural killer (NK)/T cell lymphoma
         </strong>
         – NK/T cell lymphoma, nasal type, is also associated with EBV infection [
         <a href="#rid2">
          2
         </a>
         ]. However, the EBV positive tumor cells in PLG are of B cell origin and thus positive for pan-B cell markers such as CD20; whereas the EBV positive cells in NK/T cell lymphoma are T cells. (See
         <a class="medical medical_review" href="/z/d/html/4712.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          STAGING
         </span>
         <span class="headingEndMark">
          —
         </span>
         A formal staging system for PLG has not been reported, other than that used for non-Hodgkin lymphomas. However, it is reasonable to assess the extent of disease in the lungs and other organ systems, using careful skin and neurologic examinations, and also thoracic and abdominal computed tomography (CT) scanning. The role of positron emission tomographic (PET) scanning using 18F-fluorodeoxyglucose (18F-FDG) for staging PLG is unclear, and PLG lesions do not always have increased uptake of 18F-FDG [
         <a href="#rid44">
          44-46,53,54
         </a>
         ]. The clinical relevance of such a staging approach is unknown. (See
         <a class="medical medical_review" href="/z/d/html/4696.html" rel="external">
          "Pretreatment evaluation and staging of non-Hodgkin lymphomas"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of a treatment strategy should be based upon the type of underlying immunosuppression (eg, iatrogenic, genetic, acquired), the presence and severity of symptoms, the extent of extrapulmonary involvement, and the histopathologic grade of the lesion [
         <a href="#rid2">
          2,6,7,16,23,40,50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3568135103">
         <span class="h2">
          Disease associated with immunosuppressive medication
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who have been taking an immunosuppressive medication that is associated with PLG should stop the suspect medication, if at all possible (see
         <a class="local">
          'Pathogenesis and risk factors'
         </a>
         above). For those with low grade (grade 1 or 2) disease, observation off therapy with serial (eg, over several weeks to months) clinical examinations and chest computed tomography (CT) is reasonable. [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Patients with high grade (grade 3) disease will likely need active therapy for PLG, although resolution of grade 3 disease after
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         withdrawal has been described [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Among patients with PLG associated with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         therapy, several patients had remission or stabilization of disease with methotrexate discontinuation [
         <a href="#rid32">
          32,55-58
         </a>
         ]. However, disease progression can occur despite cessation of methotrexate and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , as described in a patient with grade 3 PLG and extensive lung disease [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         In a patient who developed PLG while taking
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         and intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), these agents were discontinued and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         added for grade 3 PLG with resolution of the lung lesions [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1564063007">
         <span class="h2">
          Associated with HIV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the setting of HIV infection, resolution of lymphomatoid granulomatosis has been reported after initiation of antiretroviral therapy [
         <a href="#rid61">
          61
         </a>
         ] and after addition of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H111103638">
         <span class="h2">
          Asymptomatic low-grade pulmonary disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occasional patients are asymptomatic and have histopathologically low grade (eg, grades 1 and 2) disease confined to the lungs [
         <a href="#rid2">
          2
         </a>
         ]. These patients should be followed with serial clinical and radiologic evaluations, as this group of patients can experience a waxing and waning course, sometimes with spontaneous remission [
         <a href="#rid2">
          2,40
         </a>
         ]. If symptoms develop or radiographic disease shows progression, active therapy is usually indicated. (See
         <a class="local">
          'Symptomatic, extensive, or high-grade disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2956207828">
         <span class="h2">
          Symptomatic, extensive, or high-grade disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with symptomatic or extensive disease, grade 3 histology, progressive disease (especially with neurologic involvement), and/or recurrent disease, we recommend treatment with interferon alfa (IFNa) or systemic chemoimmunotherapy, rather than expectant management.
        </p>
        <p>
         We encourage referral to a hematology-oncology specialist for consultation and enrollment in a clinical trial. Treatment should be individualized, with consideration of disease grade, comorbidities, prior treatment, and patient preference.
        </p>
        <p>
         No prospective studies have directly compared treatments and there is no consensus. The choice of therapy should be individualized with consideration of the stage and grade of disease, comorbid conditions, and patient preference.
        </p>
        <p>
         A case series of 67 patients described treatment of low-grade disease with IFNa and high-grade disease with chemoimmunotherapy [
         <a href="#rid63">
          63
         </a>
         ]. Patients with residual or progressive disease after initial therapy crossed over to alternative therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IFNa was associated with 64 percent overall response rate (ORR; including 61 percent complete response [CR]) and 49 percent five-year progression-free survival (PFS) among 45 patients with low-grade lesions [
         <a href="#rid63">
          63
         </a>
         ]. For eight patients who were treated with IFNa after initial chemoimmunotherapy, ORR was 63 percent (including 50 percent CR). One-half of patients treated with IFNa had grade ≥3 adverse events (primarily neutropenia/leukopenia).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of 18 patients with high-grade lesions using R-EPOCH (
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , dose-adjusted
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ) was associated with 76 percent ORR (including 47 percent CR) and 63 percent five-year PFS [
         <a href="#rid63">
          63
         </a>
         ]. For patients who crossed over to DA-EPOCH-R, ORR was 67 percent (including 47 percent CR). Among patients treated with R-EPOCH, 88 percent had grade ≥3 neutropenia, and 55 percent had infections.
        </p>
        <p>
        </p>
        <p>
         Treatment with IFNa and R-EPOCH are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4486.html" rel="external">
          "Essential thrombocythemia: Treatment and prognosis", section on 'Interferon alfa'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">
          "Initial treatment of advanced stage diffuse large B cell lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4279580044">
         <span class="h2">
          Clinical trials
         </span>
         <span class="headingEndMark">
          —
         </span>
         Information about clinical trials for PLG is available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4324" target="_blank">
          clinicaltrials.gov
         </a>
         .
        </p>
        <p class="headingAnchor" id="H2606836320">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical course of lymphomatoid granulomatosis is variable [
         <a href="#rid10">
          10,12
         </a>
         ]. Approximately 20 percent of patients achieve remission without treatment, but the majority of patients experience progressive disease without treatment [
         <a href="#rid7">
          7,10,64
         </a>
         ]. The presence of histopathologic grade 2 or 3 disease and the presence of neurologic disease appear to predict a worse outcome [
         <a href="#rid7">
          7,10
         </a>
         ].
        </p>
        <p>
         In one study, treatment of grade 1 and 2 disease with interferon (IF) alpha was associated with progression-free survival (PFS) of 56 percent (median follow-up 5.1 years), while treatment of grade 3 disease with immunochemotherapy (dose-adjusted
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , DA-EPOCH-R) resulted in PFS of 44 percent (median follow-up 32 months) [
         <a href="#rid23">
          23
         </a>
         ]. In another study of 67 patients who received interferon alfa2b for low-grade disease and DA-EPOCH-R for high-grade disease (median follow-up of 15 years), the median overall survival was 20 years (95% CI 9.8–not estimable), and the 10-year overall survival was 61 percent (95% CI 47–73 percent) [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathologic description
         </strong>
         – Pulmonary lymphomatoid granulomatosis (PLG) is an uncommon Epstein-Barr virus-associated B-cell lymphoproliferative disorder characterized by multiple pulmonary nodular lesions with lymphocytic invasion of vascular walls on biopsy. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – PLG presents between the ages of 30 and 50, although patients can be affected at any age. Men are more commonly affected than women, with an estimated male to female ratio of 2:1. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The lung is the most commonly involved organ; the skin and neurologic system may be affected separately or concurrently. Involvement of other organs occurs, but is less common. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The most common presenting symptoms and signs include cough, fever, rash/nodules, malaise, weight loss, neurologic abnormalities, dyspnea, and chest pain. Lung examination is typically normal. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chest imaging studies typically show multiple ill-defined nodular opacities, predominantly in the lung bases. Lymphadenopathy is typically absent. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathology
         </strong>
         – The histopathologic diagnosis of PLG typically manifests as a triad of polymorphic lymphoid infiltrates, transmural infiltration of arteries and veins by lymphoid cells ("angiitis"), and focal areas of necrosis within the lymphoid infiltrates (well-formed granulomas are not present)  (
         <a class="graphic graphic_picture graphicRef74089 graphicRef61309" href="/z/d/graphic/74089.html" rel="external">
          picture 1A-B
         </a>
         ). Additional features are the presence of EBV-positive B cells on in situ hybridization studies, polyclonality of T cells, and usually monoclonality of B cells. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – The choice of a treatment strategy should be based upon the presence of symptoms, history of using an inciting medication, extent of extrapulmonary involvement, and careful assessment of the histopathologic grade of the lesion. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When a medication (eg,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ) is implicated, it should be stopped, if possible, and the patient observed for changes in the extent of disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For asymptomatic patients with low-grade (grades 1 and 2) disease that is confined to the lungs, disease may wax and wane or spontaneously remit, and therefore treatment is not warranted unless the disease progresses. Serial clinical and radiologic evaluations are required during observation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with extensive, symptomatic, progressive (especially with neurologic involvement), and/or recurrent disease, we recommend treatment with interferon alfa (IFNa) or systemic chemoimmunotherapy rather than expectant management (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). There is no consensus on optimal regimens; we encourage enrollment in a clinical trial. Treatment should be individualized, with consideration of comorbidities, disease grade, and patient preference. (See
         <a class="local">
          'Symptomatic, extensive, or high-grade disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The clinical course of PLG is variable, ranging from indolent to progression to large B cell lymphoma. Improved outcomes have been associated with immunochemotherapy selected based on the histologic grade. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22300596">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Dr. Harold Collard, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis. Hum Pathol 1972; 3:457.
          </a>
         </li>
         <li class="breakAll">
          Pittaluga S, Wilson WH, Jaffe ES. Lymphomatoid granulomatosis. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised Fourth Edition, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds), IARC, Lyon 2017. p.312.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson AG, Wotherspoon AC, Diss TC, et al. Lymphomatoid granulomatosis: evidence that some cases represent Epstein-Barr virus-associated B-cell lymphoma. Histopathology 1996; 29:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myers JL, Kurtin PJ, Katzenstein AL, et al. Lymphomatoid granulomatosis. Evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection. Am J Surg Pathol 1995; 19:1300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guinee D Jr, Jaffe E, Kingma D, et al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol 1994; 18:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melani C, Jaffe ES, Wilson WH. Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder. Blood 2020; 135:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaffe ES, Wilson WH. Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. Cancer Surv 1997; 30:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myers JL. Lymphomatoid granulomatosis: past, present, ... future? Mayo Clin Proc 1990; 65:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pisani RJ, DeRemee RA. Clinical implications of the histopathologic diagnosis of pulmonary lymphomatoid granulomatosis. Mayo Clin Proc 1990; 65:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katzenstein AL, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer 1979; 43:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sordillo PP, Epremian B, Koziner B, et al. Lymphomatoid granulomatosis: an analysis of clinical and immunologic characteristics. Cancer 1982; 49:2070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fauci AS, Haynes BF, Costa J, et al. Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years. N Engl J Med 1982; 306:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koss MN, Hochholzer L, Langloss JM, et al. Lymphomatoid granulomatosis: a clinicopathologic study of 42 patients. Pathology 1986; 18:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson WH, Kingma DW, Raffeld M, et al. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood 1996; 87:4531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oren H, Irken G, Kargi A, et al. A pediatric case of lymphomatoid granulomatosis with onset after completion of chemotherapy for acute myeloid leukemia. J Pediatr Hematol Oncol 2003; 25:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katzenstein AL, Doxtader E, Narendra S. Lymphomatoid granulomatosis: insights gained over 4 decades. Am J Surg Pathol 2010; 34:e35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Tuder R, Lynch DA. Lymphomatoid granulomatosis: radiologic features and pathologic correlations. AJR Am J Roentgenol 2000; 175:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morice WG, Kurtin PJ, Myers JL. Expression of cytolytic lymphocyte-associated antigens in pulmonary lymphomatoid granulomatosis. Am J Clin Pathol 2002; 118:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucantoni C, De Bonis P, Doglietto F, et al. Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. J Neurooncol 2009; 94:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishihara H, Tateishi U, Itoh T, et al. Immunohistochemical and gene rearrangement studies of central nervous system lymphomatoid granulomatosis. Neuropathology 2007; 27:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Váróczy L, Gergely L, Szakáll S, Illés A. Angiocentric lymphomatoid granulomatosis and severe hypogammaglobulinaemia. Haematologia (Budap) 2002; 32:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sebire NJ, Haselden S, Malone M, et al. Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy. J Clin Pathol 2003; 56:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song JY, Pittaluga S, Dunleavy K, et al. Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations. Am J Surg Pathol 2015; 39:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimitriades VR, Devlin V, Pittaluga S, et al. DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation. Front Pediatr 2017; 5:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costiniuk CT, Karamchandani J, Bessissow A, et al. Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report. BMC Infect Dis 2018; 18:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katherine Martin L, Porcu P, Baiocchi RA, et al. Primary central nervous system lymphomatoid granulomatosis in a patient receiving azathioprine therapy. Clin Adv Hematol Oncol 2009; 7:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph R, Chacko B, Manipadam MT, et al. Pulmonary lymphomatoid granulomatosis in a renal allograft recipient. Transpl Infect Dis 2008; 10:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfistershammer K, Petzelbauer P, Stingl G, et al. Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an 'angiocentric' histological morphology. Clin Exp Dermatol 2010; 35:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kameda H, Okuyama A, Tamaru J, et al. Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis. Clin Rheumatol 2007; 26:1585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yazdi AS, Metzler G, Weyrauch S, et al. Lymphomatoid granulomatosis induced by imatinib-treatment. Arch Dermatol 2007; 143:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barakat A, Grover K, Peshin R. Rituximab for pulmonary lymphomatoid granulomatosis which developed as a complication of methotrexate and azathioprine therapy for rheumatoid arthritis. Springerplus 2014; 3:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oiwa H, Mihara K, Kan T, et al. Grade 3 lymphomatoid granulomatosis in a patient receiving methotrexate therapy for rheumatoid arthritis. Intern Med 2014; 53:1873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connors W, Griffiths C, Patel J, Belletrutti PJ. Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease. BMC Gastroenterol 2014; 14:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López Fernández E, Curieses Luengo M, Varela Trastoy P. A rare lymphoproliferative disorder associated with immunomodulating therapy in Crohn's disease. Rev Esp Enferm Dig 2019; 111:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shanti RM, Torres-Cabala CA, Jaffe ES, et al. Lymphomatoid granulomatosis with involvement of the hard palate: a case report. J Oral Maxillofac Surg 2008; 66:2161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pereira AC, Oliveira TM, Nomelini RS, et al. Lymphomatoid granulomatosis of the vulva: case report with immunohistochemical analysis. J Obstet Gynaecol 2009; 29:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melegh Z, Sutak J, Whiteway A, et al. Lymphomatoid granulomatosis of the uterine cervix. Pathol Res Pract 2009; 205:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kappen JH, van Zaanen HC, Snelder SM, et al. Lymphomatoid granulomatosis with pulmonary and gastrointestinal involvement. BMJ Case Rep 2017; 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolaman Z, Kadiköylü G, Polatli M, et al. Migratory nodules in the lung: lymphomatoid granulomatosis. Leuk Lymphoma 2003; 44:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roschewski M, Wilson WH. Lymphomatoid granulomatosis. Cancer J 2012; 18:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mizuno T, Takanashi Y, Onodera H, et al. A case of lymphomatoid granulomatosis/angiocentric immunoproliferative lesion with long clinical course and diffuse brain involvement. J Neurol Sci 2003; 213:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins S, Helme RD. Lymphomatoid granulomatosis presenting as a progressive cervical cord lesion. Aust N Z J Med 1989; 19:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCloskey M, Catherwood M, McManus D, et al. A case of lymphomatoid granulomatosis masquerading as a lung abscess. Thorax 2004; 59:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arai H, Oshiro H, Yamanaka S, et al. Grade I lymphomatoid granulomatosis with increased uptake of [18F] fluorodeoxyglucose in positron emission tomography: a case report. J Clin Exp Hematop 2009; 49:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawai N, Miyake K, Nishiyama Y, et al. FDG-PET findings of the brain in lymphomatoid granulomatosis. Ann Nucl Med 2006; 20:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erickson BW, Cripe L, Rieger K, et al. A woman with facial papules and pulmonary nodules. Respiration 2007; 74:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols PW, Koss M, Levine AM, Lukes RJ. Lymphomatoid granulomatosis: a T-cell disorder? Am J Med 1982; 72:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipford EH Jr, Margolick JB, Longo DL, et al. Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations. Blood 1988; 72:1674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medeiros LJ, Peiper SC, Elwood L, et al. Angiocentric immunoproliferative lesions: a molecular analysis of eight cases. Hum Pathol 1991; 22:1150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colby TV. Current histological diagnosis of lymphomatoid granulomatosis. Mod Pathol 2012; 25 Suppl 1:S39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexandra G, Claudia G. Lymphomatoid granulomatosis mimicking cancer and sarcoidosis. Ann Hematol 2019; 98:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morales AT, Cignarella AG, Jabeen IS, et al. An update on IgG4-related lung disease. Eur J Intern Med 2019; 66:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tung K, Rosenthal AC, Craig FE, et al. Pitfall of 18F-FDG PET/CT in Characterization of Relapsed Multisystem Lymphomatoid Granulomatosis. J Nucl Med Technol 2018; 46:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang M, Rosenthal AC, Ashman JB, Craig FE. The Role and Pitfall of F18-FDG PET/CT in Surveillance of High Grade Pulmonary Lymphomatoid Granulomatosis. Curr Probl Diagn Radiol 2021; 50:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aiko N, Sekine A, Umeda S, et al. The Spontaneous Regression of Grade 3 Methotrexate-related Lymphomatoid Granulomatosis: A Case Report and Literature Review. Intern Med 2018; 57:3163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimada K, Matsui T, Kawakami M, et al. Methotrexate-related lymphomatoid granulomatosis: a case report of spontaneous regression of large tumours in multiple organs after cessation of methotrexate therapy in rheumatoid arthritis. Scand J Rheumatol 2007; 36:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inaba M, Ushijim S, Hirata N, et al. [Methotrexate-related lymphomatoid granulomatosis in a patient with rheumatoid arthritis]. Nihon Kokyuki Gakkai Zasshi 2011; 49:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamakawa T, Kurosawa M, Yonezumi M, et al. [Methotrexate-related lymphomatoid granulomatosis successfully treated with discontinuation of methotrexate and radiotherapy to brain]. Rinsho Ketsueki 2014; 55:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchart K, Paciencia M, Seguin A, et al. Fatal pulmonary lymphomatoid granulomatosis in a patient taking methotrexate for rheumatoid arthritis. Minerva Anestesiol 2014; 80:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burwick N, Buckley SA, Dong ZM, Richard RE. Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy. BMJ Case Rep 2016; 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kano Y, Kodaira M, Ushiki A, et al. The Complete Remission of Acquired Immunodeficiency Syndrome-associated Isolated Central Nervous System Lymphomatoid Granulomatosis: A Case Report and Review of the Literature. Intern Med 2017; 56:2497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gray TC, van Wyk AC, Goussard P, Gie RP. Lymphomatoid granulomatosis: a rare cause of cavitatory lung disease in an HIV positive child. Pediatr Pulmonol 2013; 48:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melani C, Dowdell K, Pittaluga S, et al. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial. Lancet Haematol 2023; 10:e346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James WD, Odom RB, Katzenstein AL. Cutaneous manifestations of lymphomatoid granulomatosis. Report of 44 cases and a review of the literature. Arch Dermatol 1981; 117:196.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4324 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4638966" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lymphomatoid granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4638966" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Lymphomatoid granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8910039" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lymphomatoid granulomatosis: evidence that some cases represent Epstein-Barr virus-associated B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7573693" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Lymphomatoid granulomatosis. Evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8037289" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32107539" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9547995" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2406524" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Lymphomatoid granulomatosis: past, present, ... future?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2304362" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical implications of the histopathologic diagnosis of pulmonary lymphomatoid granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/761171" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6978760" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Lymphomatoid granulomatosis: an analysis of clinical and immunologic characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7053488" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3785978" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Lymphomatoid granulomatosis: a clinicopathologic study of 42 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639820" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12571471" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A pediatric case of lymphomatoid granulomatosis with onset after completion of chemotherapy for acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21107080" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Lymphomatoid granulomatosis: insights gained over 4 decades.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11044036" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Lymphomatoid granulomatosis: radiologic features and pathologic correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12219781" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Expression of cytolytic lymphocyte-associated antigens in pulmonary lymphomatoid granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19322520" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18018473" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Immunohistochemical and gene rearrangement studies of central nervous system lymphomatoid granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12803130" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Angiocentric lymphomatoid granulomatosis and severe hypogammaglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12835306" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25321327" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28293550" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29739366" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19274043" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Primary central nervous system lymphomatoid granulomatosis in a patient receiving azathioprine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511820" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pulmonary lymphomatoid granulomatosis in a renal allograft recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19486063" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an 'angiocentric' histological morphology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17200802" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17875901" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Lymphomatoid granulomatosis induced by imatinib-treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25674479" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Rituximab for pulmonary lymphomatoid granulomatosis which developed as a complication of methotrexate and azathioprine therapy for rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25130128" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Grade 3 lymphomatoid granulomatosis in a patient receiving methotrexate therapy for rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25022612" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31021160" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A rare lymphoproliferative disorder associated with immunomodulating therapy in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18848119" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Lymphomatoid granulomatosis with involvement of the hard palate: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19358044" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Lymphomatoid granulomatosis of the vulva: case report with immunohistochemical analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19147299" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Lymphomatoid granulomatosis of the uterine cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28167690" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Lymphomatoid granulomatosis with pulmonary and gastrointestinal involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12691164" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Migratory nodules in the lung: lymphomatoid granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23006954" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Lymphomatoid granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12873757" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A case of lymphomatoid granulomatosis/angiocentric immunoproliferative lesion with long clinical course and diffuse brain involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2764816" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Lymphomatoid granulomatosis presenting as a progressive cervical cord lesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15333862" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A case of lymphomatoid granulomatosis masquerading as a lung abscess.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19474516" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Grade I lymphomatoid granulomatosis with increased uptake of [18F] fluorodeoxyglucose in positron emission tomography: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17385307" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : FDG-PET findings of the brain in lymphomatoid granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17135718" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A woman with facial papules and pulmonary nodules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6174046" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Lymphomatoid granulomatosis: a T-cell disorder?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3263153" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1743700" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Angiocentric immunoproliferative lesions: a molecular analysis of eight cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22214969" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Current histological diagnosis of lymphomatoid granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30288554" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Lymphomatoid granulomatosis mimicking cancer and sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31227290" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : An update on IgG4-related lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29884684" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Pitfall of 18F-FDG PET/CT in Characterization of Relapsed Multisystem Lymphomatoid Granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30826140" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The Role and Pitfall of F18-FDG PET/CT in Surveillance of High Grade Pulmonary Lymphomatoid Granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29877270" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The Spontaneous Regression of Grade 3 Methotrexate-related Lymphomatoid Granulomatosis: A Case Report and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17454938" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Methotrexate-related lymphomatoid granulomatosis: a case report of spontaneous regression of large tumours in multiple organs after cessation of methotrexate therapy in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21894776" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : [Methotrexate-related lymphomatoid granulomatosis in a patient with rheumatoid arthritis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24681935" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : [Methotrexate-related lymphomatoid granulomatosis successfully treated with discontinuation of methotrexate and radiotherapy to brain].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23857444" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Fatal pulmonary lymphomatoid granulomatosis in a patient taking methotrexate for rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27671987" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28824078" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The Complete Remission of Acquired Immunodeficiency Syndrome-associated Isolated Central Nervous System Lymphomatoid Granulomatosis: A Case Report and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22693139" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Lymphomatoid granulomatosis: a rare cause of cavitatory lung disease in an HIV positive child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37011643" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7212740" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cutaneous manifestations of lymphomatoid granulomatosis. Report of 44 cases and a review of the literature.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
